Πλοήγηση ανά Συγγραφέα "Papatheodoridis, G. V."
-
HBSAG LEVELS DECLINE > 10% DURING 48 WEEKS OF PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITS B (CHB) FAVORS END OF TREATMENT RESPONSE: PRELIMINARY ANALYSIS OF THE PERSEAS COHORT
Goulis, L.; Akriviadis, E.; Karatapanis, S.; Deutsch, M.; Dalekos, G. N.; Raptopoulou-Gigi, M. P.; Drakoulis, C.; Mimidis, K.; Germanidis, G.; Nikolopoulou, V.; Chounta, A.; Bakalos, G.; Papatheodoridis, G. V. (2011) -
Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort
Papatheodoridis, G. V.; Manolakopoulos, S.; Touloumi, G.; Nikolopoulou, G.; Raptopoulou-Gigi, M.; Gogos, C.; Vafiadis-Zouboulis, I.; Karamanolis, D.; Chouta, A.; Ilias, A.; Drakoulis, C.; Mimidis, K.; Ketikoglou, I.; Manesis, E.; Mela, M.; Hatzis, G.; Dalekos, G. N. (2015)Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first-line antivirals remains uncertain. ... -
IL28B polymorphisms as predictors of response to peginterferon-alfa-2a in HBeAg-negative chronic hepatitis B
Papatheodoridis, G. V.; Gatselis, N.; Goulis, I.; Karatapanis, S.; Deutsch, M.; Mimidis, K.; Drakoulis, C.; Akriviadis, E. A.; Dalekos, G. N. (2013) -
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
Papatheodoridis, G. V.; Dalekos, G. N.; Yurdaydin, C.; Buti, M.; Goulis, J.; Arends, P.; Sypsa, V.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Papaioannou, C.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L. A.; Lampertico, P. (2015)Background & Aims: The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear. We evaluated the incidence and predictors of ... -
On treatment prediction of post-treatment sustained response to Peginterferon alfa-2a for HBeAg-negative Chronic Hepatitis B (CHB) patients using HBsAg and HBV DNA levels at weeks 12 and 24: PERSEAS cohort final results
Goulis, I.; Karatapanis, S.; Akriviadis, E. A.; Deutsch, M.; Dalekos, G. N.; Raptopoulou-Gigi, M.; Mimidis, K.; Germanidis, G.; Triantos, C. K.; Drakoulis, C.; Chounta, A.; Vafiadis, I.; Hatzis, G.; Gagalis, A.; Vlachogiannakos, J.; Zintzaras, E.; Koulouris, S.; Bakalos, G.; Papatheodoridis, G. V. (2013) -
Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF)
Papatheodoridis, G. V.; Dalekos, G. N.; Yurdaydin, C.; Goulis, I.; Arends, P.; Buti, M.; Sypsa, V.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Papaioannou, C.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L.; Lampertico, P. (2013) -
Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF)
Papatheodoridis, G. V.; Dalekos, G. N.; Sypsa, V.; Yurdaydin, C.; Buti, M.; Goulis, I.; Chi, H.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Vlachogiannakos, J.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L.; Lampertico, P. (2014)